BBLG
Bone Biologics Corp Common Stock
stockNASDAQ
a publicly-held biotechnology company that is a spin off of the musculoskeletal transplant foundation (mtf) using technology discovered and licensed from ucla. bone biologics market and focus is in the regenerative medicine orthobiologics space. bone biologics was founded in 2004 by university of california professors in collaboration with an osaka university professor and a usc surgeon and acquired in 2006 by mtf as the major shareholder, who has been the primary funder since the acquisition. the company's proprietary, patented platform technology ucb-1™, exclusively licensed from ucla, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and rhesus monkey) studies that have demonstrated that the ucb-1™ technology facilitates superior normal bone growth. the company believes that as a platform technology, ucb-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.40 | 2026-10-16 | -0.63% | 3.065 |
| 1M | 0.51 | 2026-09-23 | -22.48% | 1.021 |
| 3M | 1.08 | 2026-07-23 | -63.66% | 0.378 |
| 6M | 1.35 | 2026-04-23 | -70.93% | 0.678 |
| 1Y | 2.21 | 2025-10-23 | -82.24% | 0.927 |
| 2Y | 10.26 | 2024-10-23 | -96.17% | — |
| 5Y | 6,480.00 | 2021-10-22 | -99.99% | 0.723 |
Bone Biologics Corp Common Stock (NASDAQ:BBLG) stock price today is $0.39, and today's volume is 25,138. BBLG is down 6.548% today. The 30 day average volume is 215,411. BBLG market cap is $1.08M with 2.76M shares outstanding.